US Budget Impact Model for Selinexor in Relapsed or Refractory Multiple Myeloma.
Jan BassaliIan Gopal GouldJames A KayeDeirdre MladsiJyotsna MehtaPublished in: ClinicoEconomics and outcomes research : CEOR (2020)
The model estimates a small and manageable budget impact of adopting selinexor into a third-party US payer plan, given the low prevalence of penta-refractory MM.